SMARCA1 and breast cancer: This finding, together with the observation that the different BC molecular subtypes are featured by various extents of SWI/SNF impairment as well as expression levels of metabolic enzymes, lead us to the conclusion that the alterations of SWI/SNF complex may be a signature for these cancer subtypes.